1. Home
  2. RELL vs CHRS Comparison

RELL vs CHRS Comparison

Compare RELL & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Richardson Electronics Ltd.

RELL

Richardson Electronics Ltd.

HOLD

Current Price

$17.49

Market Cap

250.7M

Sector

Technology

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.54

Market Cap

209.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RELL
CHRS
Founded
1947
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
250.7M
209.8M
IPO Year
2004
2014

Fundamental Metrics

Financial Performance
Metric
RELL
CHRS
Price
$17.49
$1.54
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.51
AVG Volume (30 Days)
157.0K
1.1M
Earning Date
04-08-2026
05-07-2026
Dividend Yield
1.75%
N/A
EPS Growth
N/A
472.00
EPS
N/A
N/A
Revenue
$208,909,000.00
N/A
Revenue This Year
$6.32
$73.08
Revenue Next Year
$7.91
$30.94
P/E Ratio
$230.96
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.37
$0.81
52 Week High
$19.86
$2.62

Technical Indicators

Market Signals
Indicator
RELL
CHRS
Relative Strength Index (RSI) 51.26 50.76
Support Level $10.17 $1.39
Resistance Level $19.40 $1.57
Average True Range (ATR) 1.03 0.10
MACD -0.19 0.02
Stochastic Oscillator 53.75 45.66

Price Performance

Historical Comparison
RELL
CHRS

About RELL Richardson Electronics Ltd.

Richardson Electronics Ltd provides engineered solutions, power grid, and microwave tubes and related consumables, power conversion, RF and microwave components, high-value flat panel detector solutions, replacement parts, tubes, and service training for diagnostic imaging equipment and customized display solutions. The company's segment includes Power and Microwave Technologies, Green Energy Solutions, Canvys, and Healthcare. The company generates the majority of its revenue from the Power and Microwave Technologies segment, which includes the power grid and microwave tube business and RF, Wireless and Power technologies.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: